Skip to Content

'
Bonnie S. Glisson, M.D.

Present Title & Affiliation

Primary Appointment

Professor of Medicine & Internist, Department of Thoracic Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX
Ashbel Smith Professor, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Bio Statement

Bonnie S. Glisson, MD is a professor and chief of head and neck medical oncology at The University of Texas MD Anderson Cancer Center. Dr Glisson graduated from Ohio State University magna cum laude with a BS and an MD. She was a resident at the University of Virginia and a fellow at the University of Florida. She is board certified in internal medicine and medical oncology.

Dr Glisson holds an Ashbel Smith Professorship in the University of Texas System and has received numerous honors and awards for education and mentoring. She has been listed numerous times in the “The Best Doctors in America” and “America’s Top Doctors”. She is a member of the American Association for Cancer Research, the American Society of Clinical Oncology, the International Association for the Study of Lung Cancer, and the American Head and Neck Society. Dr Glisson has given numerous lectures and has published dozens of articles and abstracts.

Office Address

The University of Texas M. D. Anderson Cancer Center
1515 Holcombe Blvd.
Unit Number: 432
Houston, TX 77030
Room Number: FC9.3065
Phone: (713) 792-6363
Fax: (713) 792-1220

Education & Training

Degree-Granting Education

1979 Ohio State University, Columbus, OH, MD, Medicine
1976 Ohio State University, Columbus, OH, Graduate School, Graduate School
1975 Ohio State University, Columbus, OH, BS, Magna cum laude, Human Nutrition
1971 Central-Hower High School, Akron, OH, High School Diploma, (Class Valedictorian)

Postgraduate Training

1983-1985 Research Fellowship, Pharmacology and Medical Oncology, University of Florida, Gainesville, FL
1982-1983 Clinical Fellowship, Hematology and Medical Oncology, University of Florida, Gainesville, FL
1979-1982 Clinical Residency, Internal Medicine, University of Virginia, Charlottesville, VA

Selected Publications

Peer-Reviewed Original Research Articles
1. Hanrahan EO, Kies MS, Glisson BS, Khuri FR, Feng L, Tran HT, Ginsberg LE, Truong MT, Hong WK, Kim ES. A Phase II Study of Lonafarnib (SCH66336) in Patients With Chemorefractory, Advanced Squamous Cell Carcinoma of the Head and Neck. Am J Clin Oncol. e-Pub 5/2009. PMID: 19433965.
2. Holsinger FC, Kies MS, Diaz EM, Gillenwater AM, Lewin JS, Ginsberg LE, Glisson BS, Garden AS, Ark N, Lin HY, Lee JJ, El-Naggar AK, Ki Hong W, Shin DM, Khuri FR. Durable long-term remission with chemotherapy alone for stage II to IV laryngeal cancer. J Clin Oncol 27(12). e-Pub 3/2009. PMID: 19289628.
3. Zinner RG, Komaki R, Cox JD, Glisson BS, Pisters KM, Herbst RS, Kies M, Liao Z, Hong WK, Fossella FV. Dose Escalation of Gemcitabine Is Possible with Concurrent Chest Three-Dimensional Rather than Two-Dimensional Radiotherapy: A Phase I Trial in Patients with Stage III Non-Small-Cell Lung Cancer. Int J Radiat Oncol Biol Phys 73(1):119-127, 1/2009. PMID: 18556142.
4. Saigal B, Glisson BS, Johnson FM. Dose-dependent and sequence-dependent cytotoxicity of erlotinib and docetaxel in head and neck squamous cell carcinoma. Anticancer Drugs 19(5):465-75, 6/2008. PMID: 18418213.
5. Sulman EP, Schwartz DL, Le TT, Ang KK, Morrison WH, Rosenthal DI, Ahamad A, Kies M, Glisson B, Weber R, Garden AS. Imrt Reirradiation of Head and Neck Cancer-Disease Control and Morbidity Outcomes. Int J Radiat Oncol Biol Phys 73(2):399-409, 6/2008. e-Pub 6/2008. PMID: 18556144.
6. Thariat J, Ahamad A, El-Naggar AK, Williams MD, Holsinger FC, Glisson BS, Allen PK, Morrison WH, Weber RS, Ang KK, Garden AS. Outcomes after radiotherapy for basaloid squamous cell carcinoma of the head and neck: a case-control study. Cancer 112(12):2698-709, 6/2008. e-Pub 4/2008. PMID: 18429002.
7. William WN Jr, Zinner RG, Karp DD, Oh YW, Glisson BS, Phan SC, Stewart DJ. Phase I trial of motexafin gadolinium in combination with docetaxel and cisplatin for the treatment of non-small cell lung cancer. J Thorac Oncol 2(8):745-50, 8/2007. PMID: 17762342.
8. Oh S-H, Lee O-H, Schroeder C, Oh Y, Ke S, Cha H-J, Park R-W, Onn A, Herbst R, Shiry L, Glisson BS, Li C, Lee H-Y. Antimetastatic Activity of IGFBP-3 In Lung Cancer is Mediated by IGF-Independent uPA Inhibition. Mol Cancer Ther 5(11):2685-95, 11/2006.
9. Tsao AS, Garden AS, Kies MS, Morrison W, Feng L, Lee JJ, Khuri F, Zinner R, Myers J, Papadimitrakopoulou V, Lewin J, Clayman GL, Ang KK, Glisson BS. Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck. J Clin Oncol 24(25):4163-9, 9/2006. PMID: 16943532.
10. Thomas SK, Fossella FV, Liu D, Schaerer R, Tsao AS, Kies MS, Pisters KM, Blumenschein GR, Jr, Glisson BS, Lee JJ, Herbst RS, Zinner RG. Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access program. Clin Lung Cancer 7(5):326-31, 3/2006. PMID: 16640804.
11. Johnson FM, Krug LM, Tran HT, Shoaf S, Prieto VG, Tamboli P, Peeples B, Patel J, Glisson BS. Phase I studies of imatinib mesylate combined with cisplatin and irinotecan in patients with small cell lung carcinoma. Cancer 106(2):366-74, 1/2006. PMID: 16342249.
12. Thomas S, Fossella F, Liu D, Schaerer R, Tsao A, Kies M, Pisters K, Blumenschein Jr. G, Glisson B, Lee J, Herbst R, Zinner R. Asian Ethnicity as a Predictor of Response in Patients with Non-Small-Cell Lung Cancer Treated with Gefitinib on an Expanded Access Program. Clin Lung Cancer 7(5):326-31, 2006.
13. Zinner RG, Fossella FV, Gladish GW, Glisson BS, Blumenschein GR, Jr, Papadimitrakopoulou VA, Pisters KM, Kim ES, Oh YW, Peeples BO, Ye Z, Curiel RE, Obasaju CK, Hong WK, Herbst RS. Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer. Cancer 104(11):2449-56, 12/2005. PMID: 16258975.
14. Johnson FM, Garden AS, Palmer JL, Shin DM, Morrison W, Papadimitrakopoulou V, Khuri F, Clayman G, Goepfert H, Ang KK, Hong WK, Glisson BS. A phase I/II study of neoadjuvant chemotherapy followed by radiation with boost chemotherapy for advanced T-stage nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 63(3):717-24, 11/2005. PMID: 16199307.
15. Sturgis EM, Moore BA, Glisson BS, Kies MS, Shin DM, Byers RM. Neoadjuvant chemotherapy for squamous cell carcinoma of the oral tongue in young adults: a case series. Head Neck 27(9):748-56, 9/2005. PMID: 16086413.
16. Kim ES, Kies MS, Fossella FV, Glisson BS, Zaknoen S, Statkevich P, Munden RF, Summey C, Pisters KM, Papadimitrakopoulou V, Tighiouart M, Rogatko A, Khuri FR. Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma. Cancer 104(3):561-9, 8/2005. PMID: 16028213.
17. Komaki R, Swann RS, Ettinger DS, Glisson BS, Sandler AB, Movsas B, Suh J, Byhardt RW. Phase I study of thoracic radiation dose escalation with concurrent chemotherapy for patients with limited small-cell lung cancer: Report of Radiation Therapy Oncology Group (RTOG) protocol 97-12. Int J Radiat Oncol Biol Phys 62(2):342-50, 6/2005. PMID: 15890573.
18. Rosenthal DI, Barker JL, Jr, El-Naggar AK, Glisson BS, Kies MS, Diaz EM, Jr, Clayman GL, Demonte F, Selek U, Morrison WH, Ang KK, Chao KS, Garden AS. Sinonasal malignancies with neuroendocrine differentiation: patterns of failure according to histologic phenotype. Cancer 101(11):2567-73, 12/2004. PMID: 15517582.
19. Garden AS, Harris J, Vokes EE, Forastiere AA, Ridge JA, Jones C, Horwitz EM, Glisson BS, Nabell L, Cooper JS, Demas W, Gore E. Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck. J Clin Oncol 22(14):2856-64, 7/2004. PMID: 15254053.
20. Tsimberidou AM, Medina J, Cortes J, Rios A, Glisson B, Faderl S, Kantarjian H, Garcia-Manero G. Chronic myeloid leukemia in a patient with acquired immune deficiency syndrome: complete cytogenetic response with imatinib mesylate: report of a case and review of the literature. Leuk Res 28(6):657-60, 6/2004. PMID: 15120945.
21. Tsao AS, Shin DM, Palmer JL, Lee JS, Glisson BS. Phase I evaluation of docetaxel and topotecan for patients with advanced solid tumors. Cancer 100(10):2240-5, 5/2004. PMID: 15139070.
22. Khuri FR, Glisson BS, Kim ES, Statkevich P, Thall PF, Meyers ML, Herbst RS, Munden RF, Tendler C, Zhu Y, Bangert S, Thompson E, Lu C, Wang XM, Shin DM, Kies MS, Papadimitrakopoulou V, Fossella FV, Kirschmeier P, Bishop WR, Hong WK. Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors. Clin Cancer Res 10(9):2968-76, 5/2004. PMID: 15131032.
23. Komaki R, Lee JS, Milas L, Lee HK, Fossella FV, Herbst RS, Allen PK, Liao Z, Stevens CW, Lu C, Zinner RG, Papadimitrakopoulou VA, Kies MS, Blumenschein GR, Jr, Pisters KM, Glisson BS, Kurie J, Kaplan B, Garza VP, Mooring D, Tucker SL, Cox JD. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial. Int J Radiat Oncol Biol Phys 58(5):1369-77, 4/2004. PMID: 15050312.
24. Zinner RG, Glisson BS, Fossella FV, Pisters KM, Kies MS, Lee PM, Massarelli E, Sabloff B, Fritsche HA, Jr, Ro JY, Ordonez NG, Tran HT, Yang Y, Smith TL, Mass RD, Herbst RS. Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease. Lung Cancer 44(1):99-110, 4/2004. PMID: 15013588.
25. Johnson FM, Garden A, Palmer JL, Kies M, Clayman G, Brumfield B, Khuri FR, Morrison W, Papadimitrakopoulou V, Diaz EM, Glisson BS. A Phase II study of docetaxel and carboplatin as neoadjuvant therapy for nasopharyngeal carcinoma with early T status and advanced N status. Cancer 100(5):991-8, 3/2004. PMID: 14983495.
26. Garden AS, Asper JA, Morrison WH, Schechter NR, Glisson BS, Kies MS, Myers JN, Ang KK. Is concurrent chemoradiation the treatment of choice for all patients with Stage III or IV head and neck carcinoma? Cancer 100(6):1171-8, 3/2004. PMID: 15022283.
27. Glisson B, Colevas AD, Haddad R, Krane J, El-Naggar A, Kies M, Costello R, Summey C, Arquette M, Langer C, Amrein PC, Posner M. HER2 expression in salivary gland carcinomas: dependence on histological subtype. Clin Cancer Res 10(3):944-6, 2/2004. PMID: 14871971.
28. Byers LA, Holsinger FC, Kies MS, William Jr. WN, El-Naggar AK, Lee JJ, Hu J, Lopez A, Tran HT, Yan S, Du Z, Ang KK, Glisson BS, Raso MG, Wistuba I, Myers J, Hong WK, Papadimitrakopoulou V, Lippman SM, Heymach JV. Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer. Journal of Clinical Oncology. Submitted.

Last updated: 9/16/2009